TY - JOUR
T1 - Techniques for optimizing surgical scars, Part 3
T2 - Erythema, hyperpigmentation, and hypopigmentation
AU - Potter, Kathryn
AU - Konda, Sailesh
AU - Ren, Vicky Zhen
AU - Wang, Apphia Lihan
AU - Srinivasan, Aditya
AU - Chilukuri, Suneel
N1 - Publisher Copyright:
© 2018 Pulse Marketing & Communications, LLC.
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Surgical management of benign or malignant cutaneous tumors may result in noticeable scars that are of great concern to patients, regardless of sex, age, or ethnicity. Techniques to optimize surgical scars are discussed in this three-part review. Part 3 focuses on scar revision for erythema, hyperpigmentation, and hypopigmentation. Scar revision options for erythematous scars include moist exposed burn ointment (MEBO), onion extract, silicone, methyl aminolevulinate-photodynamic therapy (MAL-PDT), pulsed dye laser, intense pulsed light (IPL), and nonablative fractional lasers. Hyperpigmented scars may be treated with tyrosinase inhibitors, IPL, and nonablative fractional lasers. Hypopigmented scars may be treated with needle dermabrasion, medical tattoos, autologous cell transplantation, prostaglandin analogues, retinoids, calcineurin inhibitors, excimer laser, and nonablative fractional lasers.
AB - Surgical management of benign or malignant cutaneous tumors may result in noticeable scars that are of great concern to patients, regardless of sex, age, or ethnicity. Techniques to optimize surgical scars are discussed in this three-part review. Part 3 focuses on scar revision for erythema, hyperpigmentation, and hypopigmentation. Scar revision options for erythematous scars include moist exposed burn ointment (MEBO), onion extract, silicone, methyl aminolevulinate-photodynamic therapy (MAL-PDT), pulsed dye laser, intense pulsed light (IPL), and nonablative fractional lasers. Hyperpigmented scars may be treated with tyrosinase inhibitors, IPL, and nonablative fractional lasers. Hypopigmented scars may be treated with needle dermabrasion, medical tattoos, autologous cell transplantation, prostaglandin analogues, retinoids, calcineurin inhibitors, excimer laser, and nonablative fractional lasers.
UR - http://www.scopus.com/inward/record.url?scp=85066479459&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066479459&partnerID=8YFLogxK
M3 - Article
C2 - 29911529
AN - SCOPUS:85066479459
SN - 1540-9740
VL - 16
SP - 113
EP - 117
JO - SKINmed
JF - SKINmed
IS - 2
ER -